GLP1R and depressive symptom measurement: Recent systemic review and meta-analysis demonstrated, that treatment with functional agonists of GLP-1 which included both GLP-1RAs and DPP4 inhibitors resulted in a significant reduction of depression rating scores and tended to be superior over control treatments, which supports the hypothesis of their antidepressant action in humans.